The gap between its revenue multiple and its cash multiple is margin, and the company is spending it on purpose.

IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.

OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.

Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.

Schechter maintains a $33 million stake after this pre-scheduled sale under a Rule 10b5-1 plan.

Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced melanoma and nationwide access to Roche's VENTANA PTEN RxDx Assay for prostate cancer. See our latest analysis for Labcorp Holdings. Labcorp Holdings has attracted more attention in recent months, with oncology diagnostics approvals and stronger earnings updates sitting alongside a 30 day share price return of 16.48% and a 1 year total...

In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded its precision oncology offering by making Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to help guide prostate cancer treatment decisions. Together with the recent FDA approval of its PGDx elio tissue complete CDx for advanced melanoma, these developments reinforce...

ALC's Q2 earnings and sales beat estimates as equipment and ocular health gains lift results, while the company raises its 2026 EPS outlook.

LH enters late 2026 with stronger growth, margin gains and raised guidance, but a rich valuation and cost risks support a measured view.

Insulet's Q2 results beat estimates on strong Omnipod demand and wider margins, but its 2026 revenue outlook takes a hit.

Prestige Consumer's Q1 earnings and revenues outpace estimates as acquisitions boost its fiscal 2027 outlook despite margin pressure.

Resmed's Q4 earnings and revenues beat estimates, but shares fall as fiscal 2027 revenue guidance trails the consensus mark.

LH shares surged 14% in a month as stronger earnings, margin gains and growth collide with a valuation above the company's five-year median.

CVS beats Q2 earnings and revenue estimates as stronger segment performance lifts results and prompts raised 2026 guidance, sending shares higher.

Henry Schein tops Q2 earnings and revenue estimates as internal sales growth accelerates and management raises its 2026 outlook, lifting shares.

Specialty testing and Central Labs fueled revenue growth and margin expansion.

DGX raised its 2026 outlook as testing demand surged, but lower-margin deals and rising project costs could temper the payoff.

Labcorp Holdings (NYSE:LH) has introduced the Marker by Labcorp Genetic Health Panel, a new consumer-focused genetic testing service. The product brings together genetic testing, counseling, and biomarker analysis in one offering for individuals looking to better understand their health risks. The launch uses Labcorp’s existing testing infrastructure alongside new AI-powered platforms to support more tailored insights for consumers. Investors watching Labcorp Holdings now have a fresh data...

Healthcare diagnostics company Labcorp Holdings (NYSE:LH) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.8% year on year to $3.73 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $14.77 billion at the midpoint. Its non-GAAP profit of $4.99 per share was 4.6% above analysts’ consensus estimates.

Quest Diagnostics' earnings beat, raised 2026 outlook and broad testing demand support momentum, but valuation, debt and margin pressure temper the buy case.

Labcorp (NYSE:LH) reported second-quarter 2026 revenue growth, margin expansion and higher adjusted earnings, prompting the laboratory services company to raise the midpoint of its full-year revenue and adjusted EPS guidance. Revenue rose 5.8% year over year to $3.7 billion, while adjusted operatin

Moby summary of Labcorp Holdings Inc.'s Q2 2026 earnings call

Specialty testing and Central Labs fueled revenue growth and margin expansion.

The telehealth company is making a bold pivot that's driving growth, but the stock's recent slide has investors wondering if the price of admission is still too high.

Labcorp Holdings Inc (LH) reports a 6% revenue increase to $3.7 billion and raises full-year 2026 guidance, driven by double-digit growth in specialty testing and robust Biopharma segment performance.

DGX's broad testing demand, payer access, advanced diagnostics and partnerships support 2026 growth as AI and automation target costs.

Labcorp's Q2 earnings and revenues surpass estimates, margins expand, and its 2026 outlook is raised, but shares fall 6% in pre-market trading.

The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Healthcare diagnostics company Labcorp Holdings (NYSE:LH) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.8% year on year to $3.73 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $14.77 billion at the midpoint. Its non-GAAP profit of $4.99 per share was 4.6% above analysts’ consensus estimates.

Labcorp (LH) delivered earnings and revenue surprises of +4.18% and +0.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Healthcare diagnostics company Labcorp Holdings (NYSE:LH) will be announcing earnings results this Thursday before market hours. Here’s what to look for.

Besides Wall Street's top-and-bottom-line estimates for Labcorp (LH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.

ZBH heads into Q2 earnings with expectations of modest revenue growth as investors watch demand trends across knees, hips and robotics.

HSIC heads into Q2 earnings with expectations for revenue and EPS growth as dental, specialty products and AI-enabled technology remain in focus.

Bank of America's trading, investment banking and digital expansion drive growth, but rising costs and market volatility pose key challenges.

Labcorp Holdings (LH) is in focus after recent commentary highlighted rising analyst optimism ahead of its June 2026 quarter earnings, with expectations for higher revenue and year over year earnings growth. See our latest analysis for Labcorp Holdings. The Labcorp Holdings share price has gained 11.9% over the past month and 17.9% year to date. The 3 year total shareholder return of 43.4% points to sustained interest alongside the more recent pickup in momentum. If you are looking beyond...

BrightSpring Health Services, Inc. (BTSG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Labcorp (LH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 9.7% over the past six months, topping the S&P 500 by 1.8 percentage points.

Labcorp Holdings recently drew attention as analysts revised their earnings estimates slightly higher ahead of its June 2026 quarter results, reflecting expectations for higher revenue and year-over-year earnings growth. This shift in analyst forecasts suggests growing confidence in Labcorp’s near-term profit outlook, adding a new layer to its existing growth story. We’ll now examine how this recent uptick in earnings expectations could influence Labcorp’s broader investment narrative and...

Labcorp (LH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Labcorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LH heads into Q2 earnings results with expectations for higher revenues and EPS, as diagnostics, specialty testing and new collaborations drive momentum.

Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

EW heads into Q2 earnings results with estimates calling for double-digit revenue growth as TAVR, TMTT and Surgical heart businesses remain in focus.

CVS Health (CVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.